Highridge Medical has finished the sale of EBI, its Bone Healing business, to healthcare investor Avista Healthcare Partners.

This transaction allows the company to focus exclusively on spine technology, driving long-term growth through investment in innovation and expansion of commercial capabilities. Highridge said it will use the transaction’s proceeds to speed investment in portfolio innovation and that commercial expansion.

The Bone Healing division specializes in non-invasive and implantable, U.S. Food and Drug Administration (FDA)-approved bone growth stimulation therapies for spine, orthopedics, and podiatry. The company will become an independent company backed by Avista.

“Divesting the Bone Healing division allows Highridge to further sharpen our focus on our most promising growth opportunities,” said Rebecca Whitney, CEO of Highridge Medical. “We are committed to driving innovation in partnership with our surgeon customers to deliver innovative spinal solutions to enhance patient outcomes.”

Highridge Medical was born in 2024 following the sale of ZimVie’s Spine division to an H.I.G. Capital affiliate. It’s headquartered in Westminster, Colo. and develops products and solutions to treat a range of spinal disorders.

Earlier this year, the company announced an exclusive distribution agreement with Osteotec to disseminate its spinal solutions in the U.K. The deal brings together Osteotec’s established presence in the U.K. with Highridge Medical’s innovative spinal solutions.